Studie des oralen TLR8-Agonisten Selgantolimod auf HBsAg bei Teilnehmern mit chronischer Hepatitis B und HIV
Sicherheit, Verträglichkeit und Wirkung des oralen TLR8-Agonisten Selgantolimod auf HBsAg bei Teilnehmern mit chronischer Hepatitis B und HIV
The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
The primary hypotheses of this study were:
- Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
- TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.
The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.
Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Rio de Janeiro, Brasilien, 21040-360
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 91350-180
- Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
-
-
-
-
-
Lima, Peru, 04
- Barranco CRS (Site ID: 11301)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
-
-
Bangkok
-
Pathum Wan, Bangkok, Thailand, 10330
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
-
-
-
-
California
-
San Diego, California, Vereinigte Staaten, 92103
- UCSD Antiviral Research Center CRS (Site ID: 701)
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- The Ponce de Leon Center CRS (Site ID: 5802)
-
-
New York
-
New York, New York, Vereinigte Staaten, 10011
- Weill Cornell Chelsea CRS (Site ID: 7804)
-
-
North Carolina
-
Greensboro, North Carolina, Vereinigte Staaten, 27401
- Greensboro CRS (Site ID: 3203)
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case CRS (Site ID: 2501)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- Univ of Pittsburgh (Site ID: 1001)
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- HIV-1 infection
- Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
- CD4+ cell count ≥350 cells/mm3
- HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
- Positive or negative HBeAg
- Negative anti-HDV
- Current CHB infection
- HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
- Quantitative HBsAg >1000 IU/mL
- Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
- Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.
Exclusion Criteria:
- Receipt of treatment for HCV within 24 weeks prior to study entry
- Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
- Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
- History of HCC or cholangiocarcinoma
- Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
- History of solid organ transplantation
- Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
- History of uveitis or posterior synechiae
- Breastfeeding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Arm A
Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks. |
Two 1.5 mg tablets taken orally once a week
Andere Namen:
|
|
Placebo-Komparator: Arm B
Participants received matching Placebo for Selgantolimod once weekly for 24 weeks. |
Two matching placebo tablets taken orally once a week |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
Zeitfenster: From study treatment initiation through Week 24
|
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
Zeitfenster: From study treatment initiation through Week 24
|
The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
Zeitfenster: Week 24
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
Zeitfenster: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
Zeitfenster: Week 24
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
Zeitfenster: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Zeitfenster: From Baseline (Entry) through Week 48
|
Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Changes From Baseline in qHBsAg Levels
Zeitfenster: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry). |
Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
|
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
Zeitfenster: From Baseline (Entry) through Week 48
|
HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Zeitfenster: From Baseline (Entry) through Week 48
|
Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Zeitfenster: From Baseline (Entry) through Week 48
|
Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Number of Participants With Plasma HIV RNA >50 Copies/mL
Zeitfenster: Weeks 2, 4, 24 and 48
|
The number of participants with detectable plasma HIV RNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
|
Number of Participants With Serum HBV DNA >50 IU/mL
Zeitfenster: Weeks 2, 4, 24 and 48
|
The number of participants with detectable serum HBV DNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Durch Blut übertragene Infektionen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des Immunsystems
- Infektionen
- RNA-Virusinfektionen
- Viruserkrankungen
- Erkrankungen des Verdauungssystems
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- DNA-Virusinfektionen
- Hepadnaviridae-Infektionen
- Hepatitis
- HIV-Infektionen
- Hepatitis B
- Selgantolimod
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- A5394
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual participant data that underlie results in the publication, after deidentification
IPD-Sharing-Zeitrahmen
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD-Sharing-Zugriffskriterien
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .